Pharsight

Drugs that contain Bempedoic Acid; Ezetimibe

1. Nexlizet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(1 year, 7 months from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(3 months ago)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(3 months ago)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(3 months ago)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(3 months ago)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(3 months ago)

US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

US11744816 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Product(NP) Feb 26, 2023

NCE-1 date: 22 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLIZET family patents

Family Patents